EpiCept’s lead product, Ceplene, is approved for marketing in the EU for the maintenance of first remission in patients with acute myeloid leukemia.
Ascalon Leverages Experienced Management Team, Strategic Partnerships for Cancer Drug Development
Ascalon International is a privately held oncology-focused drug development company based in Scottsdale, Arizona.
AesRx Aims at Two Rare Diseases In Growing Orphan Drug Market
The Newton, Mass.-based biopharmaceutical company is developing a small-molecule drug for sickle cell disease.
Adventrx Pharmaceuticals Seeks to Improve Current Cancer Drugs
The San Diego-based company seeks to improve upon existing cancer therapeutics with its reformulations of the chemotherapy drugs Navelbine and Taxotere.
Scientists Use Herpes Virus to Treat Head and Neck Cancer
Doctors in London successfully used a genetically engineered version of the herpes virus to treat head and neck cancer in a small clinical trial of 17 patients.
Colorectal Cancer Screenings Up, But Higher Numbers Could Save More Lives
More Americans are getting tested for colon cancer and breast cancer, the U.S. Centers for Disease Control (CDC) recently reported, but the numbers still aren’t high enough.
New Drug Target for Neurodegenerative Disease?
Researchers in California may have discovered new drug targets to treat an incurable hereditary disease that leads to loss of motor coordination, dementia and death.
AML Remission Maintenance, Apoptotic Inducing Therapeutics, Topical Analgesic
The Company is a biopharmaceutical company that has established a diverse drug development platform to actualize therapeutics indicated for the treatment of cancer and neuropathic pain.